LivaNova (NASDAQ:LIVN) Cut to Buy at StockNews.com

StockNews.com downgraded shares of LivaNova (NASDAQ:LIVN) from a strong-buy rating to a buy rating in a report published on Thursday.

A number of other brokerages also recently issued reports on LIVN. The Goldman Sachs Group began coverage on LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 price target for the company. Needham & Company LLC restated a “buy” rating and set a $75.00 target price on shares of LivaNova in a research note on Monday, November 25th. Mizuho dropped their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. Finally, Robert W. Baird boosted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $69.17.

LivaNova Price Performance

LivaNova stock opened at $48.82 on Thursday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The company has a fifty day simple moving average of $49.26 and a 200-day simple moving average of $50.02. The stock has a market cap of $2.65 billion, a P/E ratio of 116.24 and a beta of 1.01. LivaNova has a 12-month low of $43.15 and a 12-month high of $64.47.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.27% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Canada Pension Plan Investment Board purchased a new stake in shares of LivaNova in the second quarter valued at about $88,000. Central Pacific Bank Trust Division purchased a new stake in LivaNova during the 3rd quarter valued at approximately $178,000. Captrust Financial Advisors acquired a new stake in LivaNova during the 3rd quarter worth approximately $217,000. Sanctuary Advisors LLC purchased a new position in shares of LivaNova in the 3rd quarter valued at approximately $219,000. Finally, Edgestream Partners L.P. acquired a new position in shares of LivaNova in the third quarter valued at approximately $244,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.